Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K39/215 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2014/045254HUMAN BETACORONAVIRUS LINEAGE C AND IDENTIFICATION OF N-TERMINAL DIPEPTIDYL PEPTIDASE AS ITS VIRUS RECEPTOR
WO 27.03.2014
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/IB2013/058772 Applicant ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM Inventor HAAGMANS, Bartholomeus, Leonardus
The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.
2.WO/2006/086561NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS
WO 17.08.2006
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2006/004599 Applicant NEW YORK BLOOD CENTER Inventor JIANG, Shibo
The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.
3.560328Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
NZ 28.05.2010
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 560328 Applicant New York Blood Center Inventor Jiang, Shibo
Patent 560328 Provided is an isolated neutralizing monoclonal antibody capable of binding to the receptor binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) wherein the antibody is produced by Hybridoma 30F9 with ATCC Accession No. PTA6523.
4.2009201478The severe acute respiratory syndrome coronavirus
AU 07.05.2009
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2009201478 Applicant Novartis Vaccines and Diagnostics, Inc. Inventor
An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.
5.20040235047Methods for treatment of severe acute respiratory syndrome (SARS)
US 25.11.2004
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No 10441059 Applicant Wyeth Holdings Corporation Inventor Siber George R.

Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.

6.WO/2006/071896EPITOPE-BASED SARS VACCINE
WO 06.07.2006
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2005/047144 Applicant THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor GUO, Zhihong
This invention provides a vaccine for the infectious severe acute respiratory syndrome (SARS), which comprises antigenic epitopes from the pathogenic coronavirus. The antigenic epitopes were determined from the complementary antibodies in the plasma of convalescent SARS patients through phage display epitope mapping. These immunodominants consit of short peptide fragments distributed on various viral proteins, which includes, the spike protein, the nucleocapsid protein, the replicase 1a, and the unknown proteins 3a and 9b. Complementary antibodies targeting the immunodominant site on the spike protein effectively neutralize the coronavirus in vitro. This epitope-based vaccine avoids potential immunopathologic effects found in vaccines for other human or animal diseases since the epitopes induced safe and benificial humoral antibodies in convalescent SARS patients.
7.20060240530Compositions of coronaviruses with a recombination-resistant genome
US 26.10.2006
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No 11334877 Applicant The University of North Carolina at Chapel Hill Inventor Baric Ralph S.

The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.

8.WO/2018/160977CORONAVIRUSES, VACCINES COMPRISING THE SAME, AND METHODS FOR PREVENTING DISEASE
WO 07.09.2018
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/US2018/020678 Applicant LOYOLA UNIVERSITY CHICAGO Inventor BAKER, Susan
Coronaviruses, vaccines comprising the same, and methods for preventing disease. One embodiment of such includes a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a non-structural protein (nsp)-15, the replicase gene encoding the nsp15 and causes any change, including mutations and/or deletions, that affects the stability or activity of the nsp15.
9.20050276818Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
US 15.12.2005
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No 11132142 Applicant The Burnham Institute Inventor Godzik Adam

The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. The present invention also relates to diagnostic assays for identifying and characterizing a strain of coronavirus as being one causing severe acute respiratory syndrome.

10.WO/2015/143335METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS
WO 24.09.2015
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2015/021773 Applicant THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Inventor BARIC, Ralph
The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.